HIV treatment and prevention on every 2026 Kansas Part D plan
Pick a drug class, or type the drugs you want to check, and see which of the 12 stand-alone Part D plans in Kansas cover each one, on what tier, and with what restrictions.
- Covered
- Covered, needs prior authorization (PA) or step therapy (ST)
- Not on the formulary
- QL 60/30d = quantity limit, 60 units per 30 days
12 plans, cheapest premium first. Scroll sideways for all of them →
| Drug | Blue MedicareRx Essentials$0.00/moS5726-020 | Blue MedicareRx Value$0.70/moS5726-013 | HealthSpring Assurance Rx$6.70/moS5617-118 | Wellcare Value Script$9.60/moS4802-157 | Wellcare Classic$14.70/moS4802-088 | Humana Basic Rx Plan$15.50/moS5884-109 | Humana Value Rx Plan$55.60/moS5884-203 | Blue MedicareRx Plus$67.40/moS5726-014 | SilverScript Choice$88.30/moS5601-048 | AARP Medicare Rx Saver from UHC$105.40/moS5921-369 | Humana Premier Rx Plan$116.30/moS5884-170 | AARP Medicare Rx Preferred from UHC$147.00/moS5921-405 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biktarvybictegravir/emtricitabine/tenofovir alafenamide | Tier 525%QL 30/30d | Tier 525%QL 30/30d | Tier 525% | Tier 525% | Tier 525% | Tier 525%QL 30/30d | Tier 526%QL 30/30d | Tier 533%QL 30/30d | Tier 525% | Tier 525%QL 30/30d | Tier 533%QL 30/30d | Tier 531%QL 30/30d |
| Dovatodolutegravir and lamivudine | Tier 525%QL 30/30d | Tier 525%QL 30/30d | Tier 525% | Tier 525% | Tier 525% | Tier 525%QL 30/30d | Tier 526%QL 30/30d | Tier 533%QL 30/30d | Tier 525% | Tier 525%QL 30/30d | Tier 533%QL 30/30d | Tier 531%QL 30/30d |
| Triumeqabacavir/dolutegravir/lamivudine | Tier 430%QL 180/30d | Tier 440%QL 180/30d | Tier 431%QL 300/30d | Tier 440% | Tier 426% | Tier 435%QL 180/30d | Tier 432%QL 180/30d | Tier 440%QL 180/30d | Tier 433% | Tier 438%QL 180/30d | Tier 450%QL 180/30d | Tier 438%QL 180/30d |
| Genvoyaelvitegravir/cobicistat/emtricitabine/tenofovir alafenamide | Tier 525%QL 30/30d | Tier 525%QL 30/30d | Tier 525%QL 30/30d | Tier 525% | Tier 525% | Tier 525%QL 30/30d | Tier 526%QL 30/30d | Tier 533%QL 30/30d | Tier 525% | Tier 525%QL 30/30d | Tier 533%QL 30/30d | Tier 531%QL 30/30d |
| Odefseyemtricitabine/rilpivirine/tenofovir alafenamide | Tier 525%QL 30/30d | Tier 525%QL 30/30d | Tier 525%QL 30/30d | Tier 525% | Tier 525% | Tier 525%QL 30/30d | Tier 526%QL 30/30d | Tier 533%QL 30/30d | Tier 525% | Tier 525%QL 30/30d | Tier 533%QL 30/30d | Tier 531%QL 30/30d |
| Symtuzadarunavir/cobicistat/emtricitabine/tenofovir alafenamide | Tier 525%QL 30/30d | Tier 525%QL 30/30d | Tier 525% | Tier 525% | Tier 525% | Tier 525%QL 30/30d | Tier 526%QL 30/30d | Tier 533%QL 30/30d | Tier 525% | Tier 525%QL 30/30d | Tier 533%QL 30/30d | Tier 531%QL 30/30d |
| Julucadolutegravir and rilpivirine | Tier 525%QL 30/30d | Tier 525%QL 30/30d | Tier 525% | Tier 525% | Tier 525% | Tier 525%QL 30/30d | Tier 526%QL 30/30d | Tier 533%QL 30/30d | Tier 525% | Tier 525%QL 30/30d | Tier 533%QL 30/30d | Tier 531%QL 30/30d |
| Descovyemtricitabine and tenofovir alafenamide | Tier 525%QL 30/30d | Tier 525%QL 30/30d | Tier 525%QL 30/30d | Tier 525%QL 30/30d | Tier 525%QL 30/30d | Tier 525%QL 30/30d | Tier 526%QL 30/30d | Tier 533%QL 30/30d | Tier 525% | Tier 525%QL 30/30d | Tier 533%QL 30/30d | Tier 531%QL 30/30d |
| Truvadaemtricitabine and tenofovir disoproxil | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered |
| emtricitabine-tenofovirgeneric Truvada | Tier 430%QL 30/30d | Tier 440%QL 30/30d | Tier 431%QL 30/30d | Tier 440%QL 30/30d | Tier 426%QL 30/30d | Tier 435%QL 30/30d | Tier 432%QL 30/30d | Tier 440%QL 30/30d | Tier 433%QL 30/30d | Tier 438%QL 30/30d | Tier 450%QL 30/30d | Tier 438%QL 30/30d |
| Tivicaydolutegravir | Tier 525%QL 60/30d | Tier 525%QL 60/30d | Tier 431%QL 180/30d | Tier 525% | Tier 525% | Tier 525%QL 60/30d | Tier 526%QL 60/30d | Tier 533%QL 60/30d | Tier 525% | Tier 525%QL 60/30d | Tier 533%QL 60/30d | Tier 531%QL 60/30d |
Where a plan covers several strengths or forms of a drug, the cell shows the least restricted one. Costs are the 30-day preferred-pharmacy cost-sharing in the initial coverage phase, from the CMS 2026 formulary files. Click a plan for its full drug list.